Cardiovascular safety profile of dapoxetine during the premarketing evaluation

Drugs in R and D

Volumn 11, Issue 1, 2011, Pages 1-11

  Kowey, Peter R ^a   Mudumbi, Ramagopal V ^b   Aquilina, Joseph W ^b   DiBattiste, Peter M ^b  

^a LANKENAU HOSPITAL   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dapoxetine; Premature ejaculation; therapeutic use

Indexed keywords

DAPOXETINE; PLACEBO;

CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HEART CONDUCTION; HEART PALPITATION; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; HYPERTENSION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYNCOPE; TACHYCARDIA;

EID: 79953156439     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11587660-000000000-00000     Document Type: Review

References (46)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000
2. McMahon CG, Althof SE, Waldinger MD, et al. An evidencebased definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Mednn 2008 Jul; 5(7):1590-606 (Pubitemid 352044417)
3. Jackson G, Rosen RC, Kloner RA, et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006 Jan; 3(1):28-36
4. Basile Fasolo C, Mirone V, Gentile V, et al. Premature ejaculation: prevalence and associated conditions in a sample of 12, 558 men attending the andrology prevention week 2001 - a study of the Italian Society of Andrology (SIA). J Sex Med 2005 May; 2(3):376-82 (Pubitemid 40744378)
5. Public assessment report scientific discussion: priligy dapoxetine hydrochloride film-coated tablets, 30 and 60 mg. Läkemedelsverket Medical Products Agency, December 2008. Available from URL: http://www.lakemedelsverket. se/SPC-PIL/Pdf/par/Priligy%20film%20coated%20tablets% 2030%20and%2060%20mg.pdf [Accessed 2011 Jan 7]
6. McMahon CG. Dapoxetine for premature ejaculation. Expert Opin Pharmacother 2010 Jul; 11(10):1741-52
7. Dresser MJ, Kang D, Staehr P, et al. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J Clin Pharmacol 2006 Sep; 46(9):1023-9 (Pubitemid 44215067)
8. Modi NB, Dresser MJ, Simon M, et al. Single-and multipledose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006 Mar; 46(3):301-9 (Pubitemid 43260317)
9. Thyssen A, Sharma O, Tianmei S, et al. Pharmacokinetics of dapoxetine hydrochloride in healthy chinese, Japanese, and caucasian men. J Clin Pharmacol 2010 Dec; 50(12):1450-60
10. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62 Suppl. 3:10-21 (Pubitemid 32164676)
11. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997 Fall; 23(3):176-94 (Pubitemid 27514710)
12. Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int 2008 Sep; 102(6):668-75
13. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004 Jul; 172(1):290-4
14. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(3 Suppl. B): S55-87 (Pubitemid 28556670)
15. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm des 2004;10(20):2463-75 (Pubitemid 38997427)
16. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006 Dec; 51(14):923-9 (Pubitemid 46354056)
17. ZOLOFT (sertraline hydrochloride) [prescribing information]. New York (NY): Pfizer Inc, 2008
18. PAXIL (paroxetine hydrochloride) [prescribing information]. Research Triangle Park (NC): Glaxo Smith Kline, 2009
19. PROZAC (fluoxetine hydrochloride) [prescribing information]. Indianapolis (IN): Eli Lilly and Co, 2009
20. US Food and Drug Administration. Preliminary concept paper on the clinical evaluation of the QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; 15 November 2002. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs% 5Cprelim.pdf [Accessed 2010 Aug. 2]
21. ICH harmonized tripartite guideline E2a. Clinical safety data management: definitions and standards for expedited reporting; 27 October 1994. Available from URL: http://www.ich.org/LOB/media/MEDIA436.pdf [Accessed 2010 Aug. 2]
22. ICH Harmonized Tripartite Guideline S7A. Safety pharmacology studies for human pharmaceuticals; 8 November 2000. Available from URL: http://www.ich.org/ LOB/me dia/MEDIA504.pdf [Accessed 2010 Aug. 2]
23. ICH Harmonized Tripartite Guideline S7B. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; 12 May 2005. Available from URL: http://www.ich.org/ LOB/media/MEDIA2192.pdf [Accessed 2010 Aug. 2]
24. Modi NB, Nath R, Staehr P, et al. Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adultmale subjects. J Clin Pharmacol 2009 Jun; 49(6):634-42
25. Nilsson-Neijber A, Althof S, Gittelman M, et al. Dapoxetine treatment of men with premature ejaculation: dose-finding analysis [abstract no. P-02-163]. J Sex Med 2006; Suppl. 3:224-86.
26. Plus poster presented at 8th Congress of the European Society for Sexual Medicine; 2005 Dec. 4-7; Copenhagen
27. Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55(4):957-67
28. Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2009 Mar; 103(5):651-8
29. McMahon C, Kim SW, Park NC, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010 Jan; 7 (1 Pt 1):256-68
30. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006 Sep. 9; 368(9539):929-37 (Pubitemid 44331385)
31. Shabsigh R, Patrick DL, Rowland DL, et al. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU Int 2008 Sep; 102(7):824-8
32. Ng GA. Treating patients with ventricular ectopic beats. Heart 2006 Nov; 92(11):1707-12 (Pubitemid 44629193)
33. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. AV Chobanian (chair). U. S. Department of Health and Human Services, National Institutes of Health-National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program. NIH Publication No. 04-5230. August 2004. Available from URL: http://www.nhlbi.nih.gov/guidelines/ hypertension/jnc7full.pdf [Accessed 2011 Jan 7]
34. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002 Sep. 19; 347(12):878-85
35. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope-update 2004: executive summary. Eur Heart J 2004 Nov; 25(22):2054-72
36. Chen L, Chen MH, Larson MG, et al. Risk factors for syncope in a community-based sample (the Framingham Heart Study). Am J Cardiol 2000 May 15; 85(10):1189-93 (Pubitemid 30232812)
37. Chen-Scarabelli C, Scarabelli TM. Neurocardiogenic syncope. BMJ 2004 Aug. 7; 329(7461):336-41 (Pubitemid 39062306)
38. Grubb BP. Clinical practice: neurocardiogenic syncope. N Engl J Med 2005 Mar. 10; 352(10):1004-10
39. Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation 2000 Dec. 5; 102(23):2898-906
40. Robertson RM, Medina E, Shah N, et al. Neurally mediated syncope: pathophysiology and implications for treatment. Am J Med Sci 1999 Feb; 317(2):102-9 (Pubitemid 29521400)
41. Grubb BP. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation 2005 Jun. 7; 111(22):2997-3006 (Pubitemid 40814194)
42. Grubb BP, Karas BJ. The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances. J Interv Card Electrophysiol 1998 Dec; 2(4):325-32 (Pubitemid 128691591)
43. Theodorakis GN, Livanis EG, Leftheriotis D, et al. Head-up tilt test with clomipramine challenge in vasovagal syndrome: a new tilt testing protocol. Eur Heart J 2003 Apr; 24(7):658-63 (Pubitemid 36343199)
44. Abboud FM. Neurocardiogenic syncope. N Engl J Med 1993 Apr. 15; 328(15):1117-20 (Pubitemid 23097803)
45. Giuliano F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007 Feb; 30(2):79-84 (Pubitemid 46164860)
46. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000 Jan; 85(1):11-28